Disclosed herein are methods for enhancing an immune response in an individual in need thereof. The methods, in certain aspects, may comprise administering bacterial aldehyde dehydrogenase, a bacteria that produces aldehyde dehydrogenase, or combinations thereof to an individual. Further disclosed are compositions, such as nutritional compositions, which may comprise bacterial aldehyde dehydrogenase, a bacteria that produces aldehyde dehydrogenase, or combinations thereof.

The present invention includes novel systems, methods, and compositions for the non-endogenous production of cannabinoids in non-Cannabis plants, and preferably Glycine max or other high-biomass crops. In one embodiment, the present invention includes the generation of transgenic plant seeds, and preferably Glycine max seeds, expressing a heterologous nucleotide sequence encoding one or more heterologous enzymes necessary for the production a cannabinoid, a cannabinoid intermediate from a precursor compound. Certain precursors compound may be produced endogenously by the plant, or incorporated from a heterologous source and incorporated into the non-endogenous cannabinoid pathway.

This disclosure relates to genome-scale attenuation or knockout strategies for directing carbon flux to certain carbon based building blocks within the 7-aminoheptanoic acid (7-AHA) and 6-aminohexanoic acid (6-AHA) biosynthesis pathways, for example, to achieve reduced flux to unwanted side products while achieving increased production of desired intermediates and end products. This disclosure also relates to non-naturally occurring mutant bacterial strains comprising one or more gene disruptions in aldehyde reductase and/or aldehyde dehydrogenase genes that are generated to direct carbon flux to certain carbon based building blocks. This disclosure further relates to a method for enhancing production of carbon based building blocks by generating non-naturally occurring mutant bacterial strains, culturing said mutant bacterial strains in the presence of suitable substrates or under desired growth conditions, and substantially purifying the desired end product.

Methods for the fermentative production of four carbon alcohols is provided. Specifically, butanol, preferably isobutanol is produced by the fermentative growth of a recombinant bacterium expressing an isobutanol biosynthetic pathway.

The present application provides a process for the preparation of -methylene--butyrolactone, said process comprising the steps of: a) acetylating the C1-hydroxyl group of isoprenol to yield isoprenyl acetate; b) forming 4-acetoxy-2-methylene-butan-1-ol from said isoprenyl acetate by whole cell biotransformation, said step comprising: i) contacting a cell (CB) with a culture medium containing said isoprenyl acetate or with a culture medium contiguous with an organic phase containing said isoprenyl acetate under conditions that enable the cell to form 4-acetoxy-2-methylene-butan-1-ol from isoprenyl acetate; and, ii) optionally isolating the resultant 4-acetoxy-2-methylene-butan-1-ol, wherein said cell (CB) exhibits activity of at least one alkane monooxygenase enzyme which catalyzes the formation of 4-acetoxy-2-methylene-butan-1-ol from isoprenyl acetate; c) oxidizing said 4-acetoxy-2-methylene-butan-1-ol to yield 4-acetoxy-2-methylene butyric acid; and, d) converting said 4-acetoxy-2-methylene butyric acid to -methylene--butyrolactone by hydroxylysis to -hydroxy--methylenebutyric acid and subsequent cyclization of said -hydroxy--methylenebutyric acid.

The present disclosure provides recombinant microorganisms and methods for the production of 4-HMF, 2,4-furandimethanol, furan-2,4-dicarbaldehyde, 4-(hydroxymethyl)furoic acid, 2-formylfuran-4-carboxylate, 4-formylfuran-2-carboxylate, and/or 2,4-FDCA from a carbon source. The method provides for engineered microorganisms that express endogenous and/or exogenous nucleic acid molecules that catalyze the conversion of a carbon source into 4-HMF, 2,4-furandimethanol, furan-2,4-dicarbaldehyde, 4-(hydroxymethyl)furoic acid, 2-formylfuran-4-carboxylate, 4-formylfuran-2-carboxylate, and/or 2,4-FDCA. The disclosure further provides methods of producing polymers derived from 4-HMF, 2,4-furandimethanol, furan-2,4-dicarbaldehyde, 4-(hydroxymethyl)furoic acid, 2-formylfuran-4-carboxylate, 4-formylfuran-2-carboxylate, and/or 2,4-FDCA.

This document describes biochemical pathways for producing pimelic acid, 7-aminoheptanoic acid, 7-hydroxyheptanoic acid, heptamethylenediamine or 1,7-heptanediol by forming one or two terminal functional groups, each comprised of carboxyl, amine or hydroxyl group, in a C7 aliphatic backbone substrate. These pathways, metabolic engineering and cultivation strategies described herein rely on the C1 elongation enzymes or homolog associated with coenzyme B biosynthesis.

The present invention relates to the field of fungal biotechnology, more particularly to genetic engineering methods for the production of polyunsaturated fatty acids (PUFA) in fungal hosts selected from Rhodosporidium and Rhodotorula genera. The present invention further relates to a modified fungal host cell having reduced native aldehyde dehydrogenase (ALD 1) enzyme activity, and methods for producing omega-3 and omega-6 fatty acids and triacylglycerides, by growing said fungal host cell under suitable conditions.

The compositions contain a novel aldehyde dehydrogenase derived from a novel mutant yeast, that improve memory and cognitive function. The embodiments relate to a food and pharmaceutical composition for preventing Alzheimer's disease and Huntington disease by reducing the accumulation of lesional proteins in brain tissue. The food or pharmaceutical compositions contain a lysate of any one or a mixture thereof selected from Saccharomyces cerevisiae, KCTC13925BP, KCTC14122BP, KCTC14123BP, KCTC14983BP, KCTC14984BP and KCTC14985BP.

The disclosure relates to the field of specialty chemicals and methods for their synthesis. In embodiments, the disclosure provides viable bacterial cells which comprise heterologous dual 3-hydroxy-acyl-ACP dehydratase/isomerases, etc. The disclosure further provides monounsaturated fatty acid derivative molecules produced by the viable bacterial cells which are non-native to the bacterial cells. The disclosure further provides methods for the preparation and production of non-native monounsaturated fatty acid derivative molecules such as e.g., an 3-monounsaturated fatty acid derivative, an 5-monounsaturated fatty acid derivative, an 9-monounsaturated fatty acid derivative, an 11-monounsaturated fatty acid fatty acid derivative, etc.